monday.com is transitioning to target larger enterprise customers and integrating paid AI features, aiming to improve profitability despite slowing revenue growth. The company is reorganizing its sales teams to support this shift, expecting some short-term disruption in customer retention and cash flow through fiscal 2027. Trading at a 36.5% discount to sector median on forward EV/Sales, monday.com projects its non-GAAP operating margin to reach 24% by Q3 FY2026. Key risks include slower enterprise customer acquisition and challenges in AI and credit monetization implementation.
monday.com is the subject, with Pluang's Technology sector data providing market context. As of Nov 13, 2026 16:21 WIB, among 150 priced Technology-sector US stocks tradable on Pluang, 63 rose and 71 fell. Notable movers include MSTR at USD 111.40 with a 2.63% decline and a typical hold time of 116 days, NBIS at USD 125.60 down 2.62% with a 28-day hold time, and AMD at USD 570.21 down 2.58% with a 93-day hold time. The most notable figure is MSTR's Pluang order activity showing 72% Sell and 28% Buy.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
